Andreas Pahl

Andreas Pahl

Company: Heidelberg Pharma

Job title: Chief Scientific Officer

Seminars:

Live Discussion & Question Time 9:40 am

Read more

day: Day Two

Antibody Targeted Amanitin Conjugates (ATACs) Overcome Resistance Mechanisms to Establish New Treatment Options for Difficult to Treat Cancers 9:20 am

• ATACs represent a new class of ADCs using the payload Amanitin, introducing a novel mode of action (inhibition of RNA polymerase II) into oncology therapy. • The unique MoA facilitates killing of dormant tumor cells (CSCs, TICs) and offers new treatment options for difficult to treat cancers and high-risk patients. • HDP-101 is Heidelberg…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.